Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
inability to complete recruitment as planned
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators will conduct a randomized double blind study, to determine whether patient analgesic delivery mode preference affects pain reduction quality in non-surgical spine patients.
The patients will receive both intra-muscular and oral non-narcotic analgesics and placebo. During the study period, pain reduction parameters will be collected. At the end of the study period, the investigators will attempt to find a correlation between pre-study patient preferences and the quality of the pain reduction achieved.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IMmed | Active Comparator | Patients receiving intra-muscular medication and oral placebo |
|
| POmed | Active Comparator | Patients receiving intra-muscular placebo and oral medication |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diclofenac hydroxyethylpyrrolidine | Drug | IM/PO |
|
| Measure | Description | Time Frame |
|---|---|---|
| pain scores on visual analog scale | up to 7 days for each patient per hospitalization | visual analog scale will be mesuered before and one hour following every pain medication delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Questionnaire assessing pain and pain relief | A questionnaire will be filled immediately before and one hour following analgesic administration | Before administaration of pain control medication and one hour following analgesic administration |
| patient preference Questionnaire |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nimrod Rahamimov, M.D. | Western Galilee Hospital | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C064142 | diclofenac hydroxyethylpyrrolidine |
| D004008 | Diclofenac |
| D009966 | Orphenadrine |
| D007213 | Indomethacin |
| D014147 | Tramadol |
| D004177 | Dipyrone |
| ID | Term |
|---|---|
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| orphenadrine | Drug | IM/PO orphenadrine |
|
|
| Tramadol | Drug | IM/PO tramadol |
|
|
| Dipyrone | Drug | PO/IM Dipyrone |
|
|
every patient will be asked for his prefered analgesic delivery method |
| before first analgesic administration at the current hositalization |
| D005021 |
| Ethylamines |
| D000588 | Amines |
| D001559 | Benzhydryl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D003511 | Cyclohexanols |
| D000441 | Hexanols |
| D005233 | Fatty Alcohols |
| D000438 | Alcohols |
| D004123 | Dimethylamines |
| D008744 | Methylamines |
| D008055 | Lipids |
| D000632 | Aminopyrine |
| D047069 | Pyrazolones |
| D011720 | Pyrazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |